<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532571</url>
  </required_header>
  <id_info>
    <org_study_id>CoQ10 with PSP/CBD</org_study_id>
    <nct_id>NCT00532571</nct_id>
  </id_info>
  <brief_title>Effects of Coenzyme Q10 in PSP and CBD</brief_title>
  <official_title>Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients&#xD;
      with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive&#xD;
      supranuclear palsy (PSP) ).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Progressive Supranuclear Palsy</condition>
  <condition>Neurological Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CoQ10</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were&#xD;
             diagnosed within the past 5 years&#xD;
&#xD;
          -  Age &gt; 40&#xD;
&#xD;
          -  Subjects receiving anticholinergics, amantadine, dopamine agonists,&#xD;
             carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days&#xD;
             prior to baseline visit.&#xD;
&#xD;
          -  Patients agreeable to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or concurrent therapy with anticholinergics, amantadine,a dopamine&#xD;
             agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.&#xD;
&#xD;
          -  Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.&#xD;
&#xD;
          -  History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue&#xD;
             transplant.&#xD;
&#xD;
          -  Previous use of coenzyme Q10 within 60 days of the baseline visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Apetauerova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>June 14, 2018</last_update_submitted>
  <last_update_submitted_qc>June 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2018</last_update_posted>
  <keyword>CoQ10</keyword>
  <keyword>PSP</keyword>
  <keyword>CBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

